[Incidence of skin and non-skin cancers in Afro-Caribbean renal transplant recipients: Guadeloupe data from 2004 to 2011]. / Incidence des cancers cutanés et non cutanés chez les transplantés rénaux afro-caribéens : données guadeloupéennes de 2004 à 2011.

BACKGROUND: Cancer is the main complication of transplantation surgery. The literature concerning renal transplant recipients among the Afro-Caribbean population is scant. The aim of this study was to determine the incidence of cancer in these patients, with the secondary objective being to identify predisposing factors for cancer. PATIENTS AND METHODS: This was an epidemiological and retrospective study that included all Guadeloupians of phototype V-VI undergoing renal transplantation from 01/01/2004 to 31/12/2011. Skin cancer screening was performed before transplantation and during an annual dermatological consultation following transplantation. Screening for non-cutaneous cancers was guided by clinical symptoms or by the results of the screening examinations recommended in the current guidelines. At the study time-point (31/12/2011), all patients were examined by a dermatologist. RESULTS: One hundred and two patients were included : 42 women and 60 men (mean age: 52.1±11.6 years at transplantation). Eight cancers were diagnosed. The cumulative incidence of cancer was 7.8% at 3 years. Three factors were associated with more rapid onset of cancer: personal history or familial history of cancer, and genital lesion induced by HPV. CONCLUSION: Our results suggest a low incidence of cancer in Afro-Caribbean renal transplant patients. Personal or family history of cancer and HPV-induced genital lesions would appear to accelerate the onset of cancer in this population.

A comparative approach to the French medical missions in Brazil and in sub-Saharan Africa before the Second World War.

Franco-Brazilian cooperation in the field of microbiology and tropical diseases dates back to the onset of those disciplines. Physicians were sent over by France, namely Marchoux, Simond and Salimbeni from 1901 to 1905 to study yellow fever, and Emile Brumpt from 1913 to 1914 to teach parasitology. These missions brought in some important results. After confirming that the yellow fever agent was a filterable virus and that Stegomya (Aedes) its only vector, Simond and Marchoux clarified the biology of the mosquito and showed that sexual transmission of the virus could occur. They also set up different measures for the control of yellow fever outbreaks which Oswaldo Cruz was inspired by for his campaign against yellow fever. Emile Brumpt implemented the teaching of parasitology at the Faculty of Medicine in São Paulo and contributed to human American trypanosomiasis by defining the transmission of the disease and the cycle of the parasite responsible for it. He also developed the technique known as xenodiagnosis. Simond and Marchoux's works on yellow fever found an immediate application in French colonies, particularly in sub-Saharan Africa. However, the fight against large African endemics such as sleeping sickness, the other human trypanosomiases, could not have been carried out successfully without the contribution of mobile teams following Eugène Jamot's initiative in addition to the permanent centres which characterized the French colonial system.

Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana.

The study concerns 291 newborns and infants aged 0 to 1 year placed randomly in two groups which respectively received 0.025 and 0.05 mg Pasteur BCG by intradermal injection, between 1 December 1988 and 28 February 1989. This random test aimed to determine if the administration of one quarter dose (0.025 mg) of intradermal BCG conferred immunity comparable to that of one half (0.05 mg) while diminishing the risk of complications, in particular suppurative adenopathy, in infants of ages 0-1 year. Statistical analysis of the results showed that the 0.025 mg dose of intradermal BCG entails an immunoresponse as satisfactory as that entailed by the 0.05 mg dose, while the rate of suppurative adenitis is significantly higher in the group that received the 0.05 mg dose. It is therefore well justified to recommend a dose of 0.025 mg of intradermal Pasteur BCG for infants aged 1 year and less.